Cargando…
A clinical database to assess action levels and tolerances for the ongoing use of Mobius3D
In radiation therapy, calculation of dose within the patient contains inherent uncertainties, inaccuracies, limitations, and the potential for random error. Thus, point dose‐independent verification of such calculations is a well‐established process, with published data to support the setting of bot...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689886/ https://www.ncbi.nlm.nih.gov/pubmed/28291923 http://dx.doi.org/10.1002/acm2.12009 |
_version_ | 1783279478570483712 |
---|---|
author | Jolly, David Dunn, Leon Kenny, John |
author_facet | Jolly, David Dunn, Leon Kenny, John |
author_sort | Jolly, David |
collection | PubMed |
description | In radiation therapy, calculation of dose within the patient contains inherent uncertainties, inaccuracies, limitations, and the potential for random error. Thus, point dose‐independent verification of such calculations is a well‐established process, with published data to support the setting of both action levels and tolerances. Mobius3D takes this process one step further with a full independent calculation of patient dose and comparisons of clinical parameters such as mean target dose and voxel‐by‐voxel gamma analysis. There is currently no published data to directly inform tolerance levels for such parameters, and therefore this work presents a database of 1000 Mobius3D results to fill this gap. The data are tested for normality using a normal probability plot and found to fit this distribution for three sub groups of data; Eclipse,iPlan and the treatment site Lung. The mean (μ) and standard deviation (σ) of these sub groups is used to set action levels and tolerances at μ ± 2σ and μ ± 3σ, respectively. A global (3%, 3 mm) gamma tolerance is set at 88.5%. The mean target dose tolerance for Eclipse data is the narrowest at ± 3%, whilst iPlan and Lung have a range of −5.0 to 2.2% and −1.8 to 5.0%, respectively. With these limits in place, future results failing the action level or tolerance will fall within the worst 5% and 1% of historical results and an informed decision can be made regarding remedial action prior to treatment. |
format | Online Article Text |
id | pubmed-5689886 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-56898862018-04-02 A clinical database to assess action levels and tolerances for the ongoing use of Mobius3D Jolly, David Dunn, Leon Kenny, John J Appl Clin Med Phys Radiation Oncology Physics In radiation therapy, calculation of dose within the patient contains inherent uncertainties, inaccuracies, limitations, and the potential for random error. Thus, point dose‐independent verification of such calculations is a well‐established process, with published data to support the setting of both action levels and tolerances. Mobius3D takes this process one step further with a full independent calculation of patient dose and comparisons of clinical parameters such as mean target dose and voxel‐by‐voxel gamma analysis. There is currently no published data to directly inform tolerance levels for such parameters, and therefore this work presents a database of 1000 Mobius3D results to fill this gap. The data are tested for normality using a normal probability plot and found to fit this distribution for three sub groups of data; Eclipse,iPlan and the treatment site Lung. The mean (μ) and standard deviation (σ) of these sub groups is used to set action levels and tolerances at μ ± 2σ and μ ± 3σ, respectively. A global (3%, 3 mm) gamma tolerance is set at 88.5%. The mean target dose tolerance for Eclipse data is the narrowest at ± 3%, whilst iPlan and Lung have a range of −5.0 to 2.2% and −1.8 to 5.0%, respectively. With these limits in place, future results failing the action level or tolerance will fall within the worst 5% and 1% of historical results and an informed decision can be made regarding remedial action prior to treatment. John Wiley and Sons Inc. 2016-11-30 /pmc/articles/PMC5689886/ /pubmed/28291923 http://dx.doi.org/10.1002/acm2.12009 Text en © 2016 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Radiation Oncology Physics Jolly, David Dunn, Leon Kenny, John A clinical database to assess action levels and tolerances for the ongoing use of Mobius3D |
title | A clinical database to assess action levels and tolerances for the ongoing use of Mobius3D |
title_full | A clinical database to assess action levels and tolerances for the ongoing use of Mobius3D |
title_fullStr | A clinical database to assess action levels and tolerances for the ongoing use of Mobius3D |
title_full_unstemmed | A clinical database to assess action levels and tolerances for the ongoing use of Mobius3D |
title_short | A clinical database to assess action levels and tolerances for the ongoing use of Mobius3D |
title_sort | clinical database to assess action levels and tolerances for the ongoing use of mobius3d |
topic | Radiation Oncology Physics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689886/ https://www.ncbi.nlm.nih.gov/pubmed/28291923 http://dx.doi.org/10.1002/acm2.12009 |
work_keys_str_mv | AT jollydavid aclinicaldatabasetoassessactionlevelsandtolerancesfortheongoinguseofmobius3d AT dunnleon aclinicaldatabasetoassessactionlevelsandtolerancesfortheongoinguseofmobius3d AT kennyjohn aclinicaldatabasetoassessactionlevelsandtolerancesfortheongoinguseofmobius3d AT jollydavid clinicaldatabasetoassessactionlevelsandtolerancesfortheongoinguseofmobius3d AT dunnleon clinicaldatabasetoassessactionlevelsandtolerancesfortheongoinguseofmobius3d AT kennyjohn clinicaldatabasetoassessactionlevelsandtolerancesfortheongoinguseofmobius3d |